Summary

Persistence Market Research has recently released a comprehensive report on the global Intracranial Therapeutic Delivery market. The report delivers an in-depth evaluation of key market dynamics-drivers, trends, opportunities, and restraints-while offering detailed insights into market structure, value chain evolution, and competitive positioning across regions.

Key Insights

・Intracranial Therapeutic Delivery Market Size (2025E): US$ 2.4 Bn
・Projected Market Value (2032F): US$ 4.2 Bn
・Global Market Growth Rate (CAGR 2025-2032): 8.3%

Intracranial Therapeutic Delivery Market - Report Scope

The intracranial therapeutic delivery market encompasses the ecosystem of manufacturers, suppliers, and end-users engaged in the production, distribution, and application of intracranial therapeutic delivery products and solutions. The market serves a wide range of end-use industries, and rapid technological advancements alongside evolving end-user requirements are significantly influencing market expansion across major global regions.

Market Growth Drivers

Most systemic drugs cannot adequately penetrate the brain, as the blood-brain barrier blocks over 98% of small molecules and nearly all biologics.

Market Restraints

Therapies command prices in millions while insurance mechanisms provide limited coverage, restricting patient access and market expansion.

Market Opportunities

Advanced systems now integrate real-time MRI guidance, precision pressure-regulated pumps, and multi-port fiber-based catheters for enhanced therapeutic delivery.

Key Questions Answered in the Report

・What are the major factors driving global demand for intracranial therapeutic delivery?
・Which therapy and indication segments are witnessing the highest growth in the intracranial therapeutic delivery market?
・How is the competitive landscape evolving in the intracranial therapeutic delivery market?
・Who are the leading players in the intracranial therapeutic delivery market, and what strategies are they adopting?
・What are the emerging trends and long-term growth prospects for the global intracranial therapeutic delivery market?

Competitive Intelligence and Business Strategy

Leading players in the intracranial therapeutic delivery market are focusing on capacity expansion, product innovation, and strategic partnerships to strengthen their global footprint. Companies are investing in R&D and sustainable practices while pursuing collaborations, mergers, and regional expansion to gain a competitive edge.

Key Companies Profiled

・Novartis AG
・BioMarin
・CORESTEM Inc.
・Alaunos Therapeutics, Inc.
・Apic Bio
・Stemedica Cell Technologies, Inc.
・Voyager Therapeutics
・Bayer AG
・Abeona Therapeutics
・Spark Therapeutics

Market Segmentation

By Therapy
・Cell-based Therapy
・Gene Therapy
・Enzyme Replacement Therapy

By Indication
・Spinal Muscular Atrophy (SMA)
・Multiple Sclerosis
・Batten Disease
・Amyotrophic Lateral Sclerosis

By Region
・North America
・Europe
・East Asia
・South Asia & Oceania
・Middle East & Africa
・Latin America

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Intracranial Therapeutic Delivery Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Product Lifecycle Analysis
2.4. Intracranial Therapeutic Delivery Market: Value Chain
2.4.1. List of Raw Material Suppliers
2.4.2. List of Manufacturers
2.4.3. List of Distributors
2.4.4. Profitability Analysis
2.5. Forecast Factors - Relevance and Impact
2.6. Covid-19 Impact Assessment
2.7. PESTLE Analysis
2.8. Porter Five Force's Analysis
2.9. Geopolitical Tensions: Market Impact
2.10. Regulatory and Application Landscape
3. Macro-Economic Factors
3.1. Global Sectorial Outlook
3.2. Global GDP Growth Outlook
3.3. Global Parent Market Overview
4. Price Trend Analysis, 2018-2032
4.1. Key Highlights
4.2. Key Factors Impacting Product Prices
4.3. Prices By Product Type/Composition/Application
4.4. Regional Prices and Product Preferences
5. Global Intracranial Therapeutic Delivery Market Outlook: Historical (2018-2024) and Forecast (2025-2032)
5.1. Key Highlights
5.1.1. Market Size and Y-o-Y Growth
5.1.2. Absolute $ Opportunity
5.2. Market Size (US$ Mn) Analysis and Forecast
5.2.1. Historical Market Size Analysis, 2018-2024
5.2.2. Current Market Size Forecast, 2025-2032
5.3. Global Intracranial Therapeutic Delivery Market Outlook: Therapy
5.3.1. Introduction / Key Findings
5.3.2. Historical Market Size (US$ Mn) Analysis By Therapy, 2018-2024
5.3.3. Current Market Size (US$ Mn) Forecast By Therapy, 2025-2032
5.3.3.1. Cell-based Therapy
5.3.3.2. Gene Therapy
5.3.3.3. Enzyme Replacement Therapy
5.4. Market Attractiveness Analysis: Therapy
5.5. Global Intracranial Therapeutic Delivery Market Outlook: Indication
5.5.1. Introduction / Key Findings
5.5.2. Historical Market Size (US$ Mn) Analysis By Indication, 2018-2024
5.5.3. Current Market Size (US$ Mn) Forecast By Indication, 2025-2032
5.5.3.1. Spinal Muscular Atrophy (SMA)
5.5.3.2. Multiple Sclerosis
5.5.3.3. Batten Disease
5.5.3.4. Amyotrophic Lateral Sclerosis
5.6. Market Attractiveness Analysis: Indication
6. Global Intracranial Therapeutic Delivery Market Outlook: Region
6.1. Key Highlights
6.2. Historical Market Size (US$ Mn) Analysis By Region, 2018-2024
6.3. Current Market Size (US$ Mn) Forecast By Region, 2025-2032
6.3.1. North America
6.3.2. Europe
6.3.3. East Asia
6.3.4. South Asia and Oceania
6.3.5. Latin America
6.3.6. Middle East & Africa
6.4. Market Attractiveness Analysis: Region
7. North America Intracranial Therapeutic Delivery Market Outlook: Historical (2018-2024) and Forecast (2025-2032)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2018-2024
7.4. Current Market Size (US$ Mn) Forecast By Market Taxonomy, 2025-2032
7.4.1. By Therapy
7.4.2. By Indication
7.4.3. By Country: U.S. and Canada
7.5. Market Attractiveness Analysis
8. Europe Intracranial Therapeutic Delivery Market Outlook: Historical (2018-2024) and Forecast (2025-2032)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2018-2024
8.4. Current Market Size (US$ Mn) Forecast By Market Taxonomy, 2025-2032
8.4.1. By Therapy
8.4.2. By Indication
8.4.3. By Country: Germany, Italy, France, U.K., Spain, Russia, Rest of Europe
8.5. Market Attractiveness Analysis
9. East Asia Intracranial Therapeutic Delivery Market Outlook: Historical (2018-2024) and Forecast (2025-2032)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2018-2024
9.4. Current Market Size (US$ Mn) Forecast By Market Taxonomy, 2025-2032
9.4.1. By Therapy
9.4.2. By Indication
9.4.3. By Country: China, Japan, South Korea
9.5. Market Attractiveness Analysis
10. South Asia and Oceania Intracranial Therapeutic Delivery Market Outlook: Historical (2018-2024) and Forecast (2025-2032)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2018-2024
10.4. Current Market Size (US$ Mn) Forecast By Market Taxonomy, 2025-2032
10.4.1. By Therapy
10.4.2. By Indication
10.4.3. By Country: India, ASEAN, Oceania, Rest of South Asia
10.5. Market Attractiveness Analysis
11. Latin America Intracranial Therapeutic Delivery Market Outlook: Historical (2018-2024) and Forecast (2025-2032)
11.1. Key Highlights
11.2. Pricing Analysis
11.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2018-2024
11.4. Current Market Size (US$ Mn) Forecast By Market Taxonomy, 2025-2032
11.4.1. By Therapy
11.4.2. By Indication
11.4.3. By Country: Brazil, Mexico, Rest of Latin America
11.5. Market Attractiveness Analysis
12. Middle East & Africa Intracranial Therapeutic Delivery Market Outlook: Historical (2018-2024) and Forecast (2025-2032)
12.1. Key Highlights
12.2. Pricing Analysis
12.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2018-2024
12.4. Current Market Size (US$ Mn) Forecast By Market Taxonomy, 2025-2032
12.4.1. By Therapy
12.4.2. By Indication
12.4.3. By Country: GCC Countries, South Africa, Rest of Middle East & Africa
12.5. Market Attractiveness Analysis
13. Competitive Landscape
13.1. Market Share Analysis by Company, 2025
13.2. Competitive Dashboard
13.3. Company Profiles
13.3.1. Novartis AG
13.3.1.1. Company Overview
13.3.1.2. Product Portfolio
13.3.1.3. Financial Overview
13.3.1.4. Business Strategies and Developments
13.3.2. BioMarin
13.3.2.1. Company Overview
13.3.2.2. Product Portfolio
13.3.2.3. Financial Overview
13.3.2.4. Business Strategies and Developments
13.3.3. CORESTEM Inc.
13.3.3.1. Company Overview
13.3.3.2. Product Portfolio
13.3.3.3. Financial Overview
13.3.3.4. Business Strategies and Developments
13.3.4. Alaunos Therapeutics, Inc.
13.3.4.1. Company Overview
13.3.4.2. Product Portfolio
13.3.4.3. Financial Overview
13.3.4.4. Business Strategies and Developments
13.3.5. Apic Bio
13.3.5.1. Company Overview
13.3.5.2. Product Portfolio
13.3.5.3. Financial Overview
13.3.5.4. Business Strategies and Developments
13.3.6. Stemedica Cell Technologies, Inc.
13.3.6.1. Company Overview
13.3.6.2. Product Portfolio
13.3.6.3. Financial Overview
13.3.6.4. Business Strategies and Developments
13.3.7. Voyager Therapeutics
13.3.7.1. Company Overview
13.3.7.2. Product Portfolio
13.3.7.3. Financial Overview
13.3.7.4. Business Strategies and Developments
13.3.8. Bayer AG
13.3.8.1. Company Overview
13.3.8.2. Product Portfolio
13.3.8.3. Financial Overview
13.3.8.4. Business Strategies and Developments
13.3.9. Abeona Therapeutics
13.3.9.1. Company Overview
13.3.9.2. Product Portfolio
13.3.9.3. Financial Overview
13.3.9.4. Business Strategies and Developments
13.3.10. Spark Therapeutics
13.3.10.1. Company Overview
13.3.10.2. Product Portfolio
13.3.10.3. Financial Overview
13.3.10.4. Business Strategies and Developments
14. Appendix
14.1. Research Methodology
14.2. Report Assumptions
14.3. Acronyms and Abbreviations